Vascular endothelial growth factor (VEGF) produced by tumor cells has a central role in stimulating angiogenesis required for tumor growth. Humanized monoclonal anti-VEGF antibody (bevacizumab, Avastin), approved as a treatment for non-squamous, non-small cell lung cancer, requires administration every 3 weeks. We hypothesized that an intrapleural administration of an adeno-associated virus (AAV) vector expressing an anti-VEGF-A antibody equivalent of bevacizumab would result in sustained anti-VEGF-A localized expression within the lung and suppress metastatic tumor growth. The AAV vector AAVrh.10 alpha VEGF encodes the light chain and heavy chain complementary DNAs of monoclonal antibody A.4.6.1, a murine antibody that specifically recognizes human VEGF-A with the same antigen-binding site as bevacizumab. A metastatic lung tumor model was established in severe combined immunodeficient mice by intravenous administration of human DU145 prostate carcinoma cells. Intrapleural administration of AAVrh.10 alpha-VEGF directed long-term expression of the anti-human VEGF-A antibody in lung, as shown by sustained, high-level antihuman VEGF titers in lung epithelial lining fluid for 40 weeks, which was the duration of the study. In the AAVrh.10 alpha VEGF-treated animals, tumor growth was significantly suppressed (P < 0.05), the numbers of blood vessels and mitotic nuclei in the tumor was decreased (P < 0.05) and there was increased survival (P < 0.05). Thus, intrapleural administration of an AAVrh. 10 vector, encoding the murine monoclonal antibody equivalent of bevacizumab, effectively suppresses the growth of metastatic lung tumors, suggesting AAV-mediated gene transfer to the pleura to deliver bevacizumab locally to the lung as a novel alternative platform to conventional monoclonal antibody therapy. Gene Therapy (2010) 17, 1042-1051; doi: 10.1038/gt.2010.87; published online 1 July 2010
